Clinical Trial Update: Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study evaluating the combination of ibrutinib with obinutuzumab (GA101) in previously untreated chronic lymphocytic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Chronic Lymphocytic Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-09-15